Gemtesa (vibegron) is not a controlled substance. It has no DEA schedule classification, meaning it carries no recognized potential for abuse or dependence. You do need a prescription to get it, but it falls into the same regulatory category as medications like blood pressure pills or antibiotics, not the restricted category reserved for opioids, stimulants, or sedatives.
Why Gemtesa Is Not Controlled
The DEA assigns controlled substance schedules (I through V) to drugs that act on the brain’s reward pathways or produce physical dependence. Gemtesa doesn’t do either. It works by activating a specific type of receptor (beta-3 adrenergic) found in the bladder wall. When these receptors are activated, the bladder muscle relaxes, allowing it to hold more urine and reducing the sudden, urgent need to go. This mechanism has no overlap with the pathways involved in addiction or euphoria, which is why the drug was never considered for scheduling.
What Gemtesa Treats
Gemtesa was approved by the FDA in 2020 for overactive bladder (OAB) in adults. It targets three hallmark symptoms: the sudden urge to urinate, urinating too frequently throughout the day, and urge incontinence (leaking urine when you feel that sudden urge). It also has a specific approval for men who are already taking medication for an enlarged prostate and have OAB symptoms on top of that.
The standard dose is one 75 mg tablet taken once daily. It can be taken with or without food, which makes it straightforward to fit into a routine.
How It Compares to Older OAB Drugs
Before medications like Gemtesa existed, overactive bladder was primarily treated with anticholinergics. Those drugs work by blocking nerve signals to the bladder, but they also block the same signals in other parts of the body. That’s why anticholinergics commonly cause dry mouth, constipation, blurred vision, and cognitive side effects, particularly in older adults. Research comparing the two drug classes has found that beta-3 agonists are better tolerated, especially among elderly patients. Dry mouth, the most complained-about anticholinergic side effect, occurs at roughly placebo rates with this newer class of drugs.
Gemtesa is the second beta-3 agonist to reach the market, following mirabegron (Myrbetriq). Lab studies have shown that vibegron is a potent, selective activator of the beta-3 receptor, and its relaxation effect on bladder tissue can be enhanced when combined with certain anticholinergic medications. Some doctors prescribe both together for patients whose symptoms don’t respond adequately to one drug alone.
Common Side Effects
In a 12-week clinical trial of 545 patients taking Gemtesa, side effects were mild and relatively uncommon. The most frequently reported were:
- Headache: 4.0% (vs. 2.4% on placebo)
- Common cold symptoms (nasopharyngitis): 2.8%
- Diarrhea: 2.2%
- Nausea: 2.2%
- Upper respiratory infection: 2.0%
In a longer-term study following patients for up to a year, urinary tract infections (6.6%) and bronchitis (2.9%) also showed up at notable rates. None of these side effects relate to withdrawal or dependence, which further reflects the drug’s non-controlled status.
Prescription Requirements
Even though Gemtesa isn’t a controlled substance, you still can’t buy it over the counter. It requires a prescription because it’s a relatively new medication that needs medical oversight, particularly for patients with other health conditions or those taking multiple medications. Your pharmacy won’t need to follow the special dispensing rules that apply to controlled substances, though. There are no limits on refills, no requirement for a new prescription each month, and no monitoring through a state prescription drug database.
If you’ve been asked to show ID or faced unusual hurdles picking up Gemtesa, that’s likely a pharmacy-specific policy rather than a legal requirement tied to its drug classification.